Literature DB >> 15249298

Impact of PCV7 on invasive pneumococcal disease among children younger than 5 years: a population-based study.

Revathi R Ramani1, William N Hall, Matthew Boulton, David R Johnson, Bao-Ping Zhu.   

Abstract

We examined the impact of the heptavalent pneumococcal conjugate vaccine (PCV7) on hospital discharge rates for invasive pneumococcal disease among Michigan children younger than 5 years old. After the introduction of PCV7, the hospital discharge rate for children younger than 1 years old was significantly lower than before introduction. We correlated the decreased rates with the introduction and rapid uptake of PCV7. Lack of change in the hospital discharge rates for other age groups likely represents a slower uptake of PCV7 compared with that for children aged younger than 1 year.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15249298      PMCID: PMC1448372          DOI: 10.2105/ajph.94.6.958

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  6 in total

1.  Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era.

Authors:  K A Robinson; W Baughman; G Rothrock; N L Barrett; M Pass; C Lexau; B Damaske; K Stefonek; B Barnes; J Patterson; E R Zell; A Schuchat; C G Whitney
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

2.  Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children.

Authors:  T A Lieu; G T Ray; S B Black; J C Butler; J O Klein; R F Breiman; M A Miller; H R Shinefield
Journal:  JAMA       Date:  2000-03-15       Impact factor: 56.272

3.  Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Recomm Rep       Date:  2000-10-06

4.  American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis.

Authors: 
Journal:  Pediatrics       Date:  2000-08       Impact factor: 7.124

5.  American Academy of Pediatrics. Committee on Infectious Diseases. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis.

Authors:  G D Overturf
Journal:  Pediatrics       Date:  2000-08       Impact factor: 7.124

6.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

  6 in total
  5 in total

1.  Impact of state vaccine financing policy on uptake of heptavalent pneumococcal conjugate vaccine.

Authors:  Shannon Stokley; Kate M Shaw; Lawrence Barker; Jeanne M Santoli; Abigail Shefer
Journal:  Am J Public Health       Date:  2006-05-30       Impact factor: 9.308

2.  Routine infant vaccination of pneumococcal conjugate vaccines has decreased pneumonia across all age groups in Northern Spain.

Authors:  I Rivero-Calle; J Pardo Seco; P F Raguindin; F Alvez; J Gómez-Rial; A Salas; J Martinón Sanchez; F Martinón-Torres
Journal:  Hum Vaccin Immunother       Date:  2019-12-18       Impact factor: 3.452

3.  A Cross-Reactive Protein Vaccine Combined with PCV-13 Prevents Streptococcus pneumoniae- and Haemophilus influenzae-Mediated Acute Otitis Media.

Authors:  Hannah M Rowe; Beth Mann; Amy Iverson; Aaron Poole; Elaine Tuomanen; Jason W Rosch
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

4.  Pneumococcal conjugate vaccination in Canadian infants and children younger than five years of age: Recommendations and expected benefits.

Authors:  Carol A McClure; Michael W Ford; Jeff B Wilson; Jeff J Aramini
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-01       Impact factor: 2.471

Review 5.  A current and historical perspective on disparities in US childhood pneumococcal conjugate vaccine adherence and in rates of invasive pneumococcal disease: Considerations for the routinely-recommended, pediatric PCV dosing schedule in the United States.

Authors:  John M McLaughlin; Eric A Utt; Nina M Hill; Verna L Welch; Edward Power; Gregg C Sylvester
Journal:  Hum Vaccin Immunother       Date:  2015-09-16       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.